Mycoses in Pediatric Patients

William J. Steinbach, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advances have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drug in children and adults to offer optimal dosing strategies. Unfortunately there have been few antifungal studies conducted in children. Consequently most information for the pediatrician has been extrapolated from adult data. The breadth of antifungal data in children is expanding, however, with newer studies underway. Through the efforts of dedicated clinicians and collaboration, pediatric indications and dosing strategies will eventually be discovered that directly benefit pediatric patients.

Original languageEnglish (US)
Pages (from-to)663-678
Number of pages16
JournalInfectious Disease Clinics of North America
Volume20
Issue number3
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Mycoses
Pediatrics
Pharmacokinetics
Antifungal Agents
Safety
Pharmaceutical Preparations
Invasive Fungal Infections
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Mycoses in Pediatric Patients. / Steinbach, William J.; Walsh, Thomas J.

In: Infectious Disease Clinics of North America, Vol. 20, No. 3, 09.2006, p. 663-678.

Research output: Contribution to journalArticle

Steinbach, William J. ; Walsh, Thomas J. / Mycoses in Pediatric Patients. In: Infectious Disease Clinics of North America. 2006 ; Vol. 20, No. 3. pp. 663-678.
@article{11fa2396813d47c09610433c5dcc8d70,
title = "Mycoses in Pediatric Patients",
abstract = "For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advances have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drug in children and adults to offer optimal dosing strategies. Unfortunately there have been few antifungal studies conducted in children. Consequently most information for the pediatrician has been extrapolated from adult data. The breadth of antifungal data in children is expanding, however, with newer studies underway. Through the efforts of dedicated clinicians and collaboration, pediatric indications and dosing strategies will eventually be discovered that directly benefit pediatric patients.",
author = "Steinbach, {William J.} and Walsh, {Thomas J.}",
year = "2006",
month = "9",
doi = "10.1016/j.idc.2006.06.006",
language = "English (US)",
volume = "20",
pages = "663--678",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Mycoses in Pediatric Patients

AU - Steinbach, William J.

AU - Walsh, Thomas J.

PY - 2006/9

Y1 - 2006/9

N2 - For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advances have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drug in children and adults to offer optimal dosing strategies. Unfortunately there have been few antifungal studies conducted in children. Consequently most information for the pediatrician has been extrapolated from adult data. The breadth of antifungal data in children is expanding, however, with newer studies underway. Through the efforts of dedicated clinicians and collaboration, pediatric indications and dosing strategies will eventually be discovered that directly benefit pediatric patients.

AB - For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advances have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drug in children and adults to offer optimal dosing strategies. Unfortunately there have been few antifungal studies conducted in children. Consequently most information for the pediatrician has been extrapolated from adult data. The breadth of antifungal data in children is expanding, however, with newer studies underway. Through the efforts of dedicated clinicians and collaboration, pediatric indications and dosing strategies will eventually be discovered that directly benefit pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=33748710296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748710296&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2006.06.006

DO - 10.1016/j.idc.2006.06.006

M3 - Article

C2 - 16984874

AN - SCOPUS:33748710296

VL - 20

SP - 663

EP - 678

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 3

ER -